Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Early Detection of miRNAs in Maternal Blood Could Predict Preeclampsia

By LabMedica International staff writers
Posted on 17 Jul 2024

Preeclampsia (PE) significantly contributes to increased maternal morbidity and mortality globally, with notably high incidences in the United States where it impacts 2–8% of pregnancies. More...

This condition often leads to premature births and subsequent health issues for infants. Now, a new study indicates that early detection of specific microRNAs (miRNAs) contained in vesicles could enable the prediction of preeclampsia in pregnant individuals before the appearance of clinical symptoms.

Conducted by researchers at UCLA Health (Los Angeles, CA, USA), this study highlights the potential of a distinct set of miRNAs within extracellular vesicles (EVs)—small particles that facilitate cellular communication—as a noninvasive biomarker for preeclampsia. The analysis involved 33 participants, including a control group of seven non-pregnant women and a subgroup of 12 women with healthy pregnancies. The study also included 14 women exhibiting symptoms of preeclampsia, emphasizing early detection and prediction. Women with preeclampsia exhibited different levels of miRNAs in EVs early in pregnancy compared to those with healthy pregnancies. The research identified 148 miRNAs with varied abundances in the EVs of women with preeclampsia: 12 in greater quantities and 135 in reduced quantities compared to EVs from healthy pregnancies, showing distinct group patterns in EVs from women with the condition.

These miRNAs, detectable in blood samples from pregnant women with preeclampsia as early as the first to the second trimester, exhibit a specific pattern throughout pregnancy that shifts upon the onset of preeclampsia. Several of these miRNAs originate from the placenta and function as communicators between the placenta and other bodily organs. The researchers suggest that this panel of miRNAs could predict the development of preeclampsia symptoms, particularly those of late-onset preeclampsia. The findings published in the journal Scientific Reports propose a future where miRNAs within EVs could revolutionize the way maternal health is monitored and managed, serving as noninvasive biomarkers for the early detection of preeclampsia and enhancing understanding of the disease's pathophysiology.

“It is critical that we take steps toward early detection and prevention of pre-eclampsia,” said Dr. Sherin U. Devaskar, MD, executive chair of the Department of Pediatrics and physician-in-chief at UCLA Mattel Children’s Hospital, who led the study. “It continues to be the leading cause of maternal mortality and morbidity worldwide, and our findings underscore the potential to address this persistent public health concern.”

Related Links:
UCLA Health


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.